Shanghai Pharmaceutical Group Co., Ltd. Report for the first quarter of 2025

SZSIjust now · Announcements

Express News | Shanghai Pharmaceuticals - Qtrly Net Profit Attributable RMB1.33 Bln

Reuters9minutes ago

SH PHARMA (601607.SH): In the first quarter, Net income was 1.333 billion yuan, a year-on-year decrease of 13.56%.

Gelonghui, on April 28, reported that SH PHARMA (601607.SH) announced its first quarter report for 2025, achieving revenue of 70.763 billion yuan, a year-on-year increase of 0.87%; Net income attributable to shareholders of the listed company was 1.333 billion yuan, a year-on-year decrease of 13.56%; EPS was 0.36 yuan.

Gelonghui Finance03:38 ET

Shanghai Pharmaceuticals Completes Acquisition of SHPL

MT Newswires02:37 ET

The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.

A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.

Zhitong FinanceApr 25 23:38 ET

SH PHARMA: 2024 ANNUAL REPORT

HKEXApr 25 04:44 ET · Announcements